Therapeutic apheresis in Turkey: what it is and how it works
Therapeutic apheresis is an advanced medical treatment in which a patient's blood is passed through an extracorporeal machine, separated into its component parts, and processed to remove disease-causing elements before being returned to the body. Using automated centrifuges or selective membranes, specialists can filter out pathogenic autoantibodies, abnormal proteins, harmful cytokines, or excessive blood cells. The process occurs in a continuous, sterile circuit outside the body under close haematological supervision.
Unlike donor blood collection, therapeutic apheresis is an active clinical intervention used to treat severe autoimmune conditions, neurological crises, and haematological disorders. Hospitals offering therapeutic apheresis in Turkey provide specialized care for international patients requiring therapeutic plasma exchange or cellular depletion, coordinated with broader medical management. It is often evaluated alongside other regenerative treatments in Turkey to reduce systemic disease activity. This guide outlines how the technology works, clinical evidence, expected costs, recovery milestones, and essential clinic safety checks.
How does the apheresis filtration process work step by step?
A therapeutic apheresis session lasts between two and four hours and follows five essential clinical steps:
- Vascular access: Reliable venous access is established. Most patients use peripheral intravenous lines in both arms—one to draw blood and one to return it. If peripheral veins are inadequate, a dual-lumen central venous catheter is placed under local anaesthesia.
- Anticoagulation: As blood enters the machine tubing, an anticoagulant (usually regional citrate) is infused to prevent clotting within the circuit. Citrate binds calcium temporarily while blood is inside the device.
- Separation: The blood enters a separation chamber where centrifugation separates red cells, white cells, platelets, and plasma based on physical density, or selective membranes filter specific plasma fractions.
- Removal and replacement: The targeted pathogenic fraction is diverted into a waste collection container. When large plasma volumes are removed, an equivalent volume of replacement fluid—typically 5% human albumin or donor plasma—is infused into the return line.
- Reinfusion: The treated blood cells and replacement solution return safely to the patient's circulation. Intravenous calcium is given continuously to prevent citrate-related numbness or cramping.
Does therapeutic apheresis work, and what does clinical evidence show?
Yes, for conditions with clear scientific indications. Global practice guidelines established by the American Society for Apheresis (ASFA) categorise clinical indications according to medical evidence. In Category I disorders, therapeutic apheresis is proven first-line therapy. For example, in acute myasthenic crises, Guillain-Barré syndrome, and thrombotic thrombocytopenic purpura (TTP), rapid removal of circulating autoantibodies or ADAMTS13 inhibitors leads to measurable clinical improvement and significantly lowers mortality.
However, apheresis is not effective for every condition. It does not cure chronic illnesses or stop antibody production at the cellular level; without concurrent immunosuppressive drugs, pathogenic proteins often return. Furthermore, evidence does not support using apheresis as a general anti-ageing detox or unproven wellness therapy. Trustworthy clinics accept patients only after reviewing definitive diagnostic blood panels, nerve conduction tests, or specialist medical referrals.
Therapeutic apheresis cost in Turkey compared with the UK, US and Germany
The figures below reflect approximate cost ranges per session and for a typical multi-session treatment cycle (usually three to five sessions). They are not specific hospital quotes; each facility confirms pricing following medical review.
| Country | Approximate cost per session | Typical 3–5 session cycle |
|---|---|---|
| Turkey | €1,200 – €3,800 | €4,500 – €14,000 |
| United Kingdom | €3,200 – €7,500 | €11,000 – €28,000 |
| United States | €5,000 – €14,000 | €18,000 – €48,000 |
| Germany | €3,000 – €8,200 | €10,500 – €30,000 |
What alters the therapeutic apheresis cost: the volume of blood processed, the type and volume of replacement fluids (pharmaceutical-grade human albumin costs less than donor fresh frozen plasma), vascular access catheter placement, and inpatient versus outpatient monitoring. Multiple variables also influence the final therapeutic apheresis price. Treatment packages in Turkey commonly include baseline laboratory tests, medical specialist oversight, nursing care, single-use consumable filter kits, and local transfers. You can request a clear breakdown through our free quote service before making travel arrangements.
Therapeutic plasma exchange, cytapheresis or red blood cell exchange?
Therapeutic apheresis includes several distinct techniques tailored to specific blood components:
| Method | Target component | Best suited to | Typical limits |
|---|---|---|---|
| Therapeutic Plasma Exchange (TPE) | Blood plasma and circulating antibodies | Myasthenia gravis, Guillain-Barré, TTP, autoimmune crises | Requires replacement albumin or plasma; does not halt antibody synthesis |
| Therapeutic Cytapheresis | Pathological white cells or excess platelets | Hyperleukocytosis in leukaemia, severe thrombocythaemia | Rapid temporary cell reduction; underlying marrow disease needs chemotherapy |
| Red Blood Cell Exchange | Abnormal or sickled red blood cells | Sickle cell disease complications, severe malaria | Requires antigen-matched donor units; carry transfusion risks |
The clinical team selects the method based on your diagnosis and blood markers. For an in-depth explanation of plasma filtration, see our guide to plasmapheresis.
Which medical conditions can be treated with therapeutic apheresis?
Therapeutic apheresis is utilized across multiple medical disciplines when harmful circulating elements can be cleared from the bloodstream:
- Neurology: Acute exacerbations of myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), and Guillain-Barré syndrome.
- Haematology: Thrombotic thrombocytopenic purpura (TTP), hyperviscosity syndrome in paraproteinaemias, and extreme leukocytosis.
- Nephrology and Autoimmunity: Anti-GBM disease (Goodpasture syndrome), systemic lupus erythematosus with organ involvement, and rapidly progressive glomerulonephritis.
- Transplantation: Desensitisation for ABO-incompatible kidney transplants and treatment of acute antibody-mediated organ rejection; read more on targeted plasmapheresis protocols.
- Metabolic medicine: Familial hypercholesterolaemia refractory to maximum medication, managed with selective lipoprotein filtration.
What clinical results and symptom changes can you realistically expect?
Unlike cosmetic treatments evaluated through aesthetic photographs, therapeutic apheresis is assessed through objective clinical measurements and symptom relief. In acute conditions, patients frequently experience noticeable functional improvement within 24 to 72 hours as circulating toxic substances decline. For example, myasthenia gravis patients often regain muscle strength and swallowing function, while patients with hyperviscosity experience immediate relief from headaches and vision disturbances.
Laboratory tests confirm efficacy: a single plasma exchange cycle typically removes 60% to 70% of circulating target antibodies, with consecutive sessions achieving over 85% reduction. However, apheresis does not repair irreversible nerve damage or eradicate the immune cells that manufacture antibodies. Lasting remission requires ongoing medical therapy directed by your consultant.
Who is a good candidate, and who is not?
Good candidates are patients with a medically confirmed diagnosis meeting ASFA Category I or II criteria, possessing adequate cardiovascular stability to handle fluid shifts, and having viable vascular access routes.
You are less suited if you have:
- Severe, uncompensated hemodynamic instability or uncontrolled cardiac arrhythmias.
- Active systemic sepsis or uncontrolled bacterial infection that increases central line complications.
- Known severe allergic reactions to human albumin, replacement plasma solutions, or machine line sterilising agents.
- Severe uncorrected hypocalcaemia that could worsen with citrate anticoagulation.
- Vague, unverified symptoms without diagnostic laboratory or neurophysiological confirmation.
Your trip to Turkey and recovery step by step
Most international patients travelling for therapeutic apheresis Turkey stay between 7 and 14 days, allowing time for 3 to 5 treatment sessions spaced 24 to 48 hours apart.
On arrival, comprehensive blood tests, cardiovascular clearance, and vein checks are conducted. During each session, you rest in a treatment bed while clinical staff monitor vital signs, fluid balance, and calcium levels. When the session finishes, the puncture site is dressed, and you rest for one to two hours before returning to your hotel.
Day-to-day therapeutic apheresis recovery is generally smooth. Mild fatigue is common during the first 24 hours, so quiet rest and generous fluid intake are recommended. Strenuous exercise should be avoided on treatment days. If a central venous catheter was placed, nursing staff maintain dressing changes to prevent infection. Once the final session and post-treatment blood tests are completed, the catheter is removed and your travel clearance is issued. To understand how appointments and clinic transfers are arranged, explore how it works before booking flights.
Risks and complications of therapeutic apheresis
According to registries from the World Apheresis Association (WAA) and the British Committee for Standards in Haematology (BCSH), therapeutic apheresis is safe when performed in regulated hospital settings, with minor side effects occurring in approximately 5% to 8% of sessions.
- Citrate reactions: Numbness or tingling around the mouth, shivering, or hand cramps caused by temporary drops in blood calcium. These are promptly corrected by oral or intravenous calcium.
- Hypotension: Temporary light-headedness from fluid shifts, quickly managed by slowing the procedure rate and giving fluid boluses.
- Vascular access issues: Bruising or swelling at peripheral puncture sites; central lines carry small risks of infection, haematoma, or thrombosis.
- Allergic reactions: Mild hives or itching from replacement plasma or albumin, usually managed with antihistamines.
- Coagulation changes: Temporary reduction in clotting factors and platelets following large plasma exchanges, resolving within 24 to 48 hours.
How to choose a hospital in Turkey, red flags and questions to ask
Therapeutic apheresis should only be performed in licensed tertiary hospitals with certified haematology or nephrology departments, modern transfusion medicine laboratories, and on-site intensive care facilities.
Watch for key red flags: clinics offering apheresis in non-hospital cosmetic suites, marketing apheresis as an anti-ageing detox, quoting flat prices without reviewing medical records, or lacking a qualified supervising haematologist.
Questions to ask your medical team:
- Is the apheresis suite based within a fully equipped tertiary hospital?
- Will a board-certified haematologist directly supervise my care?
- What specific replacement fluids are included in my treatment plan?
- Will vascular access be peripheral or through a central catheter?
- What emergency and ICU support is available on-site if complications arise?
- How will follow-up medical reports be shared with my doctor at home?
To evaluate your eligibility and receive an itemised plan from qualified medical specialists, request a free quote with your recent medical summary.
Hospitals with Regenerative Medicine in Turkey
Frequently asked questions
Therapeutic apheresis is a medical procedure that removes pathogenic components from a patient's blood using an automated device. Blood is drawn, separated into plasma and cellular fractions, filtered to extract disease-causing antibodies, abnormal proteins, or excessive cells, and returned to the patient with appropriate replacement fluids.
Yes, for established indications defined by the American Society for Apheresis. It rapidly reduces circulating autoantibodies, immune complexes, or toxic cells during acute crises such as myasthenia gravis or Guillain-Barré syndrome. However, it does not stop disease-causing antibody production, meaning ongoing medication is essential to maintain long-term remission.
Individual sessions in Turkey typically range from €1,200 to €3,800, with a complete three-to-five session cycle costing approximately €4,500 to €14,000. Final pricing depends on replacement fluid volumes, specialized single-use filter kits, catheter placement, and inpatient monitoring requirements confirmed after reviewing your medical history.
Results are measured through clinical recovery and laboratory blood markers rather than visual photographs. A full cycle typically clears 80% to 90% of circulating target antibodies, leading to noticeable symptom improvements such as restored muscle strength, reduced nerve inflammation, or lower blood viscosity within days of treatment.
Physical recovery after an individual session takes about 24 hours. Most patients experience mild fatigue or dizziness and rest quietly in their hotel. Normal light daily activities can usually be resumed the following day, provided the vascular catheter site remains dry, clean, and undisturbed.
The apheresis procedure itself is not painful. Discomfort is generally limited to initial needle insertions for peripheral intravenous access or the local anaesthetic injection if a central venous catheter is required. During filtration, mild tingling around the mouth from anticoagulant citrate may occur, which is quickly relieved with calcium.
Apheresis provides rapid temporary reduction of circulating disease factors. Because it removes circulating proteins rather than the cells producing them, antibody levels can rebound within two to four weeks. Sustained disease control requires ongoing immunosuppressive or disease-modifying medical therapies prescribed by your specialist.
The treatment is safe when performed in licensed hospital environments by trained haematology teams. Registry data show mild, reversible side effects—such as transient tingling from low calcium or temporary blood pressure drops—in 5% to 8% of sessions. Serious complications are rare and promptly managed with hospital protocols.
Plasmapheresis is one specific type of therapeutic apheresis focused exclusively on separating and removing liquid plasma containing antibodies or toxins. Therapeutic apheresis is a broader medical term that also encompasses cellular depletion techniques, such as removing excess white blood cells, platelets, or abnormal red blood cells.
Patients usually stay in Turkey for 7 to 14 days. This timeframe allows for initial pre-treatment haematology assessments, three to five apheresis sessions scheduled on alternate days, post-treatment blood monitoring, safe catheter removal, and final travel clearance from the medical team.